Murali Janakiram (@JanakiramMurali) ranks #14 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 13 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: AZD0120, JNJ-5322, UK-MRA RADAR. CMS Open Payments lists $33,700 in 2025 general payments.
At a Glance
- 4 posts naming a trial since ASH 2025
- 4 trials discussed by name
- Multiple Myeloma: US #14, Global #17 · 13 physicians engaged
- Leading physician voice: #3 of 3 physicians on UK-MRA RADAR
- Presented at IMS 2026 in 2026
- CMS Open Payments lists $33,700 in 2025 general payments.
This Month
What Murali Janakiram has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #14 | #17 | 56/100 | 13 | 17 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Murali Janakiram presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- IMS 2026 · Oral (abstract OA-55)Poor outcomes post sequential BCMA and GPRC5D exposure can be improved by subsequent targeted agents vs conventional therapy (IMWG)
- IMS 2026 · PosterMezigdomide following ide-cel in RRMM is safe and deepens responses (PA-304, first author)
What Colleagues Are Saying About Murali Janakiram
2026 posts by fellow physicians that mention @JanakiramMurali, quoted word for word.
🚨 @ASH_hematology police: @JanakiramMurali is clearly tweeting while actively moderating his #ASH25 session 🤣 Joking, of course - these are great data and absolutely worth tweeting about! https://t.co/wbJMni0zVo
Trials Murali Janakiram Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| AZD0120 | 1 | — | Nov 9, 2025 |
| JNJ-5322 | 1 | — | Nov 9, 2025 |
| UK-MRA RADAR | 1 | #3 of 3 | Nov 9, 2025 |
| AQUILA | 1 | #8 of 8 | Nov 9, 2025 |
Murali Janakiram on AZD0120
8.11319 - AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy -n=25 -ORR-100% -no Gr 3 CRS, no ICANS, mostly Gr 1,2 -n=5, MRD eval. -100% -no HLH, long term neuro tox Ciltacel --> Anitocel --> AZD0120. The evolution of safer BCMA CART constructs and one time treatment
Murali Janakiram on JNJ-5322
7. 5322- Trispecific JNJ-5322 @DoctorAKrishnan n=36 ORR-100%, 12 mo PFS- 96% 1 patient died due to inf. CRS- Gr 1 and 2 -52% q4wk dosing Bi vs Tri- can't get this soon enough in clinic. Need to know whether this is better in BCMA relapsed MM. Ph 3 planned
Murali Janakiram on UK-MRA RADAR
10. DH UHR MM- UKMRA RADAR N=70 IsaVRDC*4 -> ASCT --> Isa VRD *4 --> IsaR maintenance 66.7% MRD neg 12 mo - results very similar to CONCEPT with IsaKRD It is very close to our current practice of DVRD / IsaVRD and easier to adopt
Murali Janakiram on AQUILA
4. SMM- AQUILA - Dara in SMM @VincentRK -long-term PFS benefit across all MWG 2020 -most pronounced benefit in the high-risk subgroup. - Early Dara tx for high-risk SMM no detrimental impact on stem cell yield. How to Rx after progression [my opinion]- CART/ BsAb
Murali Janakiram’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Wow its happening.... Cure / long term remission in early relapse MM Dara-Tec vs DPD/DVD -PFS @ 36 mo (HR, 0.17; 95% CI, 0.12-0.23)-83.4% vs 29.7% -OS (HR, 0.46; 95% CI, 0.32-0.65)-83.3% and 65.0% Any grade infections- 96.5% and 84.1% of Tec-Dara and DPd/DVd pts, respectively;
This will be the next question to answer in the field . Dara- Tec shd have a good uptake in the community. The way I see it currently is that - Ciltacel in later lines has data with a 33% chance of remission at 5 yrs - Hence it opens up good choices for patients . Some of my https://t.co/L3N9XVtiqx
Industry Payments
CMS Open Payments · 2025 general payments
$33,700 across 22 payments